Stem cell program wins key court ruling, poised to issue grants
By San Francisco Chronicle,
San Francisco Chronicle
| 11. 30. 2005
California's embattled Proposition 71 stem cell program took a big step Tuesday toward overcoming lawsuits that have blocked its first grants from being issued.
Alameda County Superior Court Judge Bonnie Sabraw denied essentially every legal argument brought by the plaintiffs in litigation alleging that Prop. 71 violated the state Constitution because it would allow taxpayer-backed bond revenues to be distributed without direct legislative control.
The Prop. 71 program was created by state voters in November 2004 with authority to disperse $3 billion in grants during the next 10 years, mostly intended to advance controversial embryonic stem cell research. A state agency called the California Institute for Regenerative Medicine has been created and based in San Francisco.
Lawsuits challenging the institute's plans were filed by taxpayer groups and an anti-abortion bioethics organization, frustrating research advocates who say stem cells are key to creating a radical new kind of cell-based medicine that is potentially capable of curing such maladies as Parkinson's disease, diabetes and spinal cord injuries.
Now, the program's leadership hopes to move forward by January with a stopgap funding plan...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...